Immuron Limited’s SEC filings document its foreign private issuer disclosures and ASX announcements furnished on Form 6-K. The filings include half-year financial reports, strategic updates and investor presentations describing the company’s oral polyclonal antibody platform, Hyper-Immune products, Travelan®, ProIBS®, and clinical programs for gastrointestinal infectious diseases.
The filing record also covers shareholder meeting results, small-holding share sale facility disclosures, R&D Tax Incentive notices, regional sales updates, and governance authorizations by the board. These documents provide formal disclosures on operating results, research and development funding, ordinary-share matters, and public-company reporting obligations for IMRN’s ASX and Nasdaq-traded securities.
Immuron Ltd executive Flavio Palumbo has filed an initial ownership report showing his equity interests in the company. He directly holds 1,142,909 Ordinary Shares. He also holds 640,824 Performance Rights, each linked to Ordinary Shares, with a zero exercise price and an expiration date of June 30, 2029. These performance rights vest only when specified non-market key performance indicators and performance milestones are achieved, after which they can be exercised any time until expiration.
Immuron Ltd director Daniel Jude Pollock has filed an initial Form 3 showing his share and option holdings. He reports direct ownership of 568,750 Ordinary Shares and an additional 174,480 Ordinary Shares held indirectly through joint ownership with his spouse. Pollock also holds options over 1,000,000 Ordinary Shares with a USD exercise price of $0.0789 expiring on October 3, 2029, and options over 333,333 Ordinary Shares with a USD exercise price of $0.1040 expiring on August 20, 2028. Footnotes explain these option grants vest in staged annual installments and that the exercise prices were originally denominated in Australian dollars and translated into U.S. dollars using an exchange rate of AUD 1.00 = USD 0.7172.
Immuron Limited used this report to share an investor presentation highlighting its oral immunotherapy focus, commercial products and partnering strategy. The company sells Travelan for traveler’s diarrhea and ProIBS for irritable bowel syndrome, while developing pipeline assets IMM-124E and IMM-529 for infectious gut diseases.
Management plans to partner IMM-124E and IMM-529 so licensees fund clinical development and commercialization in exchange for upfront fees, milestones and royalties. Immuron reported FY26 year-to-date global sales revenue of A$5.7 million, third-quarter revenue of A$1.5 million, and cash of A$10.0 million as of December 31, 2025, supporting its over-the-counter business.
Immuron Ltd director and Chairman of the Board Paul Gerard Brennan filed an initial Form 3 detailing his option holdings in the company. He holds options over 1,000,000 Ordinary Shares at an exercise price of $0.0789 per share, expiring on October 3, 2029, and options over 666,667 Ordinary Shares at an exercise price of $0.1793 per share, expiring on November 21, 2027. Footnotes explain that these options vest in staged annual installments between November 24, 2024 and November 24, 2028, with portions becoming exercisable each year as service-based vesting conditions are met. The exercise prices were originally set in Australian dollars and translated into U.S. dollars using a Reserve Bank of Australia exchange rate.
Immuron Limited filed a Form 6-K to share an Australian Securities Exchange announcement that its CEO, Steven Lydeamore, will present virtually at the Emerging Growth Conference on 7 May 2026 from 10:15am to 10:45am U.S. Eastern Time. The notice includes registration and question-submission details for the event.
The accompanying presentation materials describe Immuron’s focus on orally delivered, targeted polyclonal antibodies for infectious diseases and highlight key products, including Travelan® for travelers’ diarrhea, investigational candidate IMM-529 for recurrent C. difficile infection, and ProIBS® for irritable bowel syndrome symptoms.
Immuron Ltd Chief Scientific Officer Jerry Kanellos filed an initial ownership report showing his existing equity position. He directly holds 333,000 Ordinary Shares of Immuron.
He also holds Performance Rights over 272,134 underlying Ordinary Shares with a 0.0000 exercise price expiring on June 30, 2029, and additional Performance Rights over 179,664 underlying Ordinary Shares with a 0.0000 exercise price expiring on July 12, 2027. A footnote states these Performance Rights became exercisable as to 217,707 shares on July 23, 2025 and 54,427 shares on October 29, 2025.
Immuron Ltd filed an initial statement of beneficial ownership on Form 3 for Aaron James Laurita, who serves as Chief Financial Officer. The filing does not report any share transactions or holdings in either common stock or derivative securities, indicating this is a baseline regulatory disclosure as he becomes a reporting insider.
Immuron Ltd director Jeannette Anne Joughin has disclosed option holdings over the company’s Ordinary Shares. She holds options over 1,000,000 Ordinary Shares with an exercise price of $0.0789 per share, expiring on October 3, 2029. These options became exercisable as to 333,333 shares on December 9, 2024, and will become exercisable as to 333,333 shares on December 9, 2026 and 333,334 shares on December 9, 2027.
She also holds options over 333,333 Ordinary Shares with an exercise price of $0.0932 per share, expiring on June 19, 2028. Both option grants are reported as directly owned and reflect existing derivative positions rather than new market purchases or sales.
Immuron Ltd’s Chief Executive Officer Steven George Lydeamore has filed an initial ownership report. He directly holds 3,155,047 Ordinary Shares. He also holds 1,778,734 Performance Rights that vest upon achievement of performance milestones and options over 1,430,000 Ordinary Shares with a USD exercise price of $0.0861 per share, expiring on June 27, 2026.
Immuron Ltd director Ravi Savarirayan has filed an initial Form 3 detailing his ownership in the company. He reports direct ownership of 409,090 Ordinary Shares and indirect ownership of 468,750 Ordinary Shares through joint ownership with Sophie Beaumont.
He also holds options over 1,000,000 Ordinary Shares at an exercise price of $0.0789 per share, expiring on October 3, 2029, and options over 333,333 Ordinary Shares at an exercise price of $0.1040 per share, expiring on August 20, 2028. Footnotes describe staged vesting of these options across 2025–2028 and indicate the exercise prices were originally denominated in Australian dollars and translated into U.S. dollars using a Reserve Bank of Australia exchange rate.